ArticleScientific reports2024
Occurrence of protease-like catalytic activity in the polyclonal IgG in schizophrenia and bipolar disorder.
Article in Scientific reports, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
Neuro-immune dysfunction and inflammation are said to be involved in the aetiology of major mental illnesses. This study describes the assessment of the protease-like catalytic function of serum IgG in psychiatric disorders, schizophrenia and bipolar disorder, along with healthy controls of Indian ethnicity. Systemic lupus erythematosus patients experiencing neuropsychiatry conditions were included as comparators for the comprehensive evaluation of IgG catalytic function. The catalytic activity of serum IgG was determined using the generic peptide substrate Pro-Phe-Arg-methylcoumarylamide, and then the apparent kinetic data was computed. Compared to healthy controls (n = 25), the activity of those with schizophrenia (n = 30) was found to be 11-fold higher. The neuropsychiatry lupus patients (n = 25) exhibited 2.7 times less activity than the schizophrenia group. The IgG activity of the bipolar patients' (n = 30) were found to be 2.9 and 12 times higher than lupus and healthy controls. IgG activity showed a modest, no significant, link with PANSS positive and negative disease scores, in a subset of schizophrenia patients. The study's findings express presence of catalytic antibodies in the blood as well as neuro-immune dysfunction in major psychosis disorders. In addition, subsets of schizophrenia patients indicate presence of autoimmune component in them.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.